Adapted Treatment of Epstein-Barr Virus Infection to Prevent Posttransplant Lymphoproliferative Disorder After Heart Transplantation

Epstein-Barr Virus-Related Post-Transplant Lymphoproliferative Disorders: Pathogenetic Insights for Targeted Therapy

(2011) J. P. Nourse et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Pre-emptive rituximab based on viraemia and T cell reconstitution: a highly effective strategy for the prevention of Epstein-Barr virus-associated lymphoproliferative disease following stem cell transplantation

(2011) Austen Worth et al.   BRITISH JOURNAL OF HAEMATOLOGY

Spectrum of Cancer Risk Among US Solid Organ Transplant Recipients

(2011) Eric A. Engels et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

Sequential treatment with rituximab followed by CHOP chemotherapy in adult B-cell post-transplant lymphoproliferative disorder (PTLD): the prospective international multicentre phase 2 PTLD-1 trial

(2011) Ralf Trappe et al.   LANCET ONCOLOGY

Malignancy After Heart Transplantation: Incidence, Prognosis and Risk Factors

(2008) M. G. Crespo-Leiro et al.   AMERICAN JOURNAL OF TRANSPLANTATION

Evaluation of the Epstein-Barr Virus R-Gene Quantification Kit in Whole Blood with Different Extraction Methods and PCR Platforms

(2007) Samira Fafi-Kremer et al.   JOURNAL OF MOLECULAR DIAGNOSTICS